Study finds among outpatients with mild to moderate COVID-19, treatment with fluvoxamine does not reduce duration of symptoms Post author: Post published:November 22, 2023 Post category:uncategorized Researchers investigate the effects of high-dose fluvoxamine among patients with mild-to-moderate COVID-19. You Might Also Like Muscle fat infiltration predicts heart disease risk better than BMI, study finds January 21, 2025 Upper respiratory microbiome shows age, sex, and lifestyle impacts, study finds August 5, 2024 Patients facing death are opting for a lifesaving heart device — but at what risk? December 19, 2023